Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKesson
AstraZeneca
Merck
Medtronic

Last Updated: August 19, 2022

Investigational Drug Information for Pracinostat


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Pracinostat?

Pracinostat is an investigational drug.

There have been 10 clinical trials for Pracinostat. The most recent clinical trial was a Phase 2 trial, which was initiated on June 23rd 2017.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, and Syndrome. The leading clinical trial sponsors are Helsinn Healthcare SA, MEI Pharma, Inc., and M.D. Anderson Cancer Center.

There are seventy-eight US patents protecting this investigational drug and nine hundred and twelve international patents.

Recent Clinical Trials for Pracinostat
TitleSponsorPhase
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaMedical College of WisconsinPhase 1
A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The BodyQuotient SciencesPhase 1
A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The BodyHelsinn Healthcare SAPhase 1

See all Pracinostat clinical trials

Clinical Trial Summary for Pracinostat

Top disease conditions for Pracinostat
Top clinical trial sponsors for Pracinostat

See all Pracinostat clinical trials

US Patents for Pracinostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pracinostat See Plans and Pricing Histone deacetylase inhibitors and methods for use thereof REACTION BIOLOGY CORP. (Malvern, PA) See Plans and Pricing
Pracinostat See Plans and Pricing Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA) See Plans and Pricing
Pracinostat See Plans and Pricing Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA) See Plans and Pricing
Pracinostat See Plans and Pricing Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids Cantex Pharmaceuticals, Inc. (Weston, FL) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pracinostat

Drugname Country Document Number Estimated Expiration Related US Patent
Pracinostat World Intellectual Property Organization (WIPO) WO2017030892 2035-08-14 See Plans and Pricing
Pracinostat Australia AU2015339012 2034-10-31 See Plans and Pricing
Pracinostat Brazil BR112017008945 2034-10-31 See Plans and Pricing
Pracinostat Canada CA2966005 2034-10-31 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKesson
AstraZeneca
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.